{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T19:24:59Z","timestamp":1794857099455,"version":"4.9.1"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373790"],"award-info":[{"award-number":["82373790"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-64552-2","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T11:11:24Z","timestamp":1761736284000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Dynamic clinical trial success rates for drugs in the 21st century"],"prefix":"10.1038","volume":"16","author":[{"given":"Ying","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5263-3438","authenticated-orcid":false,"given":"Yintao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hangwei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianbo","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongning","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghai","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xichen","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaixuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunqing","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0768-1676","authenticated-orcid":false,"given":"Yanzhong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanqing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianyi","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5768-2714","authenticated-orcid":false,"given":"Haibin","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8069-0053","authenticated-orcid":false,"given":"Feng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"key":"64552_CR1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41591-024-03434-4","volume":"31","author":"K Zhang","year":"2025","unstructured":"Zhang, K. et al. Artificial intelligence in drug development. Nat. Med. 31, 45\u201359 (2025).","journal-title":"Nat. Med."},{"key":"64552_CR2","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/nbt.2786","volume":"32","author":"M Hay","year":"2014","unstructured":"Hay, M., Thomas, D. W., Craighead, J. L., Economides, C. & Rosenthal, J. Clinical development success rates for investigational drugs. Nat. Biotechnol. 32, 40\u201351 (2014).","journal-title":"Nat. Biotechnol."},{"key":"64552_CR3","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/d41573-019-00074-z","volume":"18","author":"H Dowden","year":"2019","unstructured":"Dowden, H. & Munro, J. Trends in clinical success rates and therapeutic focus. Nat. Rev. Drug Discov. 18, 495\u2013496 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"64552_CR4","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/d41573-025-00036-8","volume":"24","author":"S Phares","year":"2025","unstructured":"Phares, S., Phillip, K. & Trusheim, M. Clinical development success rates for durable cell and gene therapies. Nat. Rev. Drug Discov. 24, 329\u2013330 (2025).","journal-title":"Nat. Rev. Drug Discov."},{"key":"64552_CR5","doi-asserted-by":"publisher","first-page":"104291","DOI":"10.1016\/j.drudis.2025.104291","volume":"30","author":"Schuhmacher","year":"2025","unstructured":"Schuhmacher, Hinder, A., Brief, M., Gassmann, E. & Hartl, O. D. Benchmarking R&D success rates of leading pharmaceutical companies: an empirical analysis of FDA approvals (2006-2022). Drug Discov. Today 30, 104291 (2025).","journal-title":"Drug Discov. Today"},{"key":"64552_CR6","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.tips.2018.03.003","volume":"39","author":"MM Attwood","year":"2018","unstructured":"Attwood, M. M., Rask-Andersen, M. & Schioth, H. B. Orphan drugs and their impact on pharmaceutical development. Trends Pharm. Sci. 39, 525\u2013535 (2018).","journal-title":"Trends Pharm. Sci."},{"key":"64552_CR7","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/biostatistics\/kxx069","volume":"20","author":"CH Wong","year":"2019","unstructured":"Wong, C. H., Siah, K. W. & Lo, A. W. Estimation of clinical trial success rates and related parameters. Biostatistics 20, 273\u2013286 (2019).","journal-title":"Biostatistics"},{"key":"64552_CR8","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/clpt.2009.295","volume":"87","author":"JA DiMasi","year":"2010","unstructured":"DiMasi, J. A., Feldman, L., Seckler, A. & Wilson, A. Trends in risks associated with new drug development: success rates for investigational drugs. Clin. Pharm. Ther. 87, 272\u2013277 (2010).","journal-title":"Clin. Pharm. Ther."},{"key":"64552_CR9","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.drudis.2021.12.010","volume":"27","author":"K Fernando","year":"2022","unstructured":"Fernando, K. et al. Achieving end-to-end success in the clinic: Pfizer\u2019s learnings on R&D productivity. Drug Discov. Today 27, 697\u2013704 (2022).","journal-title":"Drug Discov. Today"},{"key":"64552_CR10","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/nrd1470","volume":"3","author":"I Kola","year":"2004","unstructured":"Kola, I. & Landis, J. Can the pharmaceutical industry reduce attrition rates?. Nat. Rev. Drug Discov. 3, 711\u2013715 (2004).","journal-title":"Nat. Rev. Drug Discov."},{"key":"64552_CR11","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1111\/cts.12980","volume":"14","author":"S Yamaguchi","year":"2021","unstructured":"Yamaguchi, S., Kaneko, M. & Narukawa, M. Approval success rates of drug candidates based on target, action, modality, application, and their combinations. Clin. Transl. Sci. 14, 1113\u20131122 (2021).","journal-title":"Clin. Transl. Sci."},{"key":"64552_CR12","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/bjh.17892","volume":"196","author":"C Duetz","year":"2022","unstructured":"Duetz, C. et al. The wider perspective: twenty years of clinical trials in myelodysplastic syndromes. Br. J. Haematol. 196, 329\u2013335 (2022).","journal-title":"Br. J. Haematol."},{"key":"64552_CR13","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3233\/JAD-215699","volume":"87","author":"CK Kim","year":"2022","unstructured":"Kim, C. K. et al. Alzheimer\u2019s disease: key insights from two decades of clinical trial failures. J. Alzheimers Dis. 87, 83\u2013100 (2022).","journal-title":"J. Alzheimers Dis."},{"key":"64552_CR14","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/clpt.2013.117","volume":"94","author":"JA DiMasi","year":"2013","unstructured":"DiMasi, J. A., Reichert, J. M., Feldman, L. & Malins, A. Clinical approval success rates for investigational cancer drugs. Clin. Pharm. Ther. 94, 329\u2013335 (2013).","journal-title":"Clin. Pharm. Ther."},{"key":"64552_CR15","doi-asserted-by":"publisher","first-page":"e619","DOI":"10.1016\/S1470-2045(19)30491-7","volume":"20","author":"N Li","year":"2019","unstructured":"Li, N. et al. Changes in clinical trials of cancer drugs in mainland China over the decade 2009-18: a systematic review. Lancet Oncol. 20, e619\u2013e626 (2019).","journal-title":"Lancet Oncol."},{"key":"64552_CR16","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1002\/cpt.1627","volume":"107","author":"JA DiMasi","year":"2020","unstructured":"DiMasi, J. A. et al. Development times and approval success rates for drugs to treat infectious diseases. Clin. Pharm. Ther. 107, 324\u2013332 (2020).","journal-title":"Clin. Pharm. Ther."},{"key":"64552_CR17","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/ALN.0000000000004265","volume":"137","author":"DP Maher","year":"2022","unstructured":"Maher, D. P., Wong, C. H., Siah, K. W. & Lo, A. W. Estimates of probabilities of successful development of pain medications: an analysis of pharmaceutical clinical development programs from 2000 to 2020. Anesthesiology 137, 243\u2013251 (2022).","journal-title":"Anesthesiology"},{"key":"64552_CR18","doi-asserted-by":"publisher","DOI":"10.1162\/99608f99692.e99600c99150e99608","author":"AW Lo","year":"2020","unstructured":"Lo, A. W., Siah, K. W. & Wong, C. H. Estimating probabilities of success of vaccine and other anti-infective therapeutic development programs. Harv. Data Sci. Rev. https:\/\/doi.org\/10.1162\/99608f99692.e99600c99150e99608 (2020).","journal-title":"Harv. Data Sci. Rev."},{"key":"64552_CR19","first-page":"D1031","volume":"48","author":"Y Wang","year":"2020","unstructured":"Wang, Y. et al. Therapeutic target database 2020: enriched resource for facilitating research and early development of targeted therapeutics. Nucleic Acids Res. 48, D1031\u2013D1041 (2020).","journal-title":"Nucleic Acids Res."},{"key":"64552_CR20","doi-asserted-by":"publisher","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","volume":"46","author":"DS Wishart","year":"2018","unstructured":"Wishart, D. S. et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 46, D1074\u2013D1082 (2018).","journal-title":"Nucleic Acids Res."},{"key":"64552_CR21","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/d41573-019-00124-6","volume":"18","author":"KL Miller","year":"2019","unstructured":"Miller, K. L., Rabinovitz, D. & Kerr, K. W. Transition probabilities for clinical trials: investigating individual diseases. Nat. Rev. Drug Discov. 18, 658 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"64552_CR22","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/nrd.2016.85","volume":"15","author":"K Smietana","year":"2016","unstructured":"Smietana, K., Siatkowski, M. & Moller, M. Trends in clinical success rates. Nat. Rev. Drug Discov. 15, 379\u2013380 (2016).","journal-title":"Nat. Rev. Drug Discov."},{"key":"64552_CR23","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1159\/000442446","volume":"91","author":"JT Tam","year":"2016","unstructured":"Tam, J. T., Parker, J. L., Anastasopulos, D. & Balter, M. S. Clinical trial risk in chronic obstructive pulmonary disease: the effects of drug class and inclusion criteria. Respiration 91, 79\u201386 (2016).","journal-title":"Respiration"},{"key":"64552_CR24","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1111\/obr.12299","volume":"16","author":"HT Hussain","year":"2015","unstructured":"Hussain, H. T., Parker, J. L. & Sharma, A. M. Clinical trial success rates of anti-obesity agents: the importance of combination therapies. Obes. Rev. 16, 707\u2013714 (2015).","journal-title":"Obes. Rev."},{"key":"64552_CR25","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1097\/MJT.0b013e318269198f","volume":"21","author":"JA DiMasi","year":"2014","unstructured":"DiMasi, J. A. Pharmaceutical R&D performance by firm size: approval success rates and economic returns. Am. J. Ther. 21, 26\u201334 (2014).","journal-title":"Am. J. Ther."},{"key":"64552_CR26","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1093\/jnci\/djad082","volume":"115","author":"A Arfe","year":"2023","unstructured":"Arfe, A., Narang, C., DuBois, S. G., Reaman, G. & Bourgeois, F. T. Clinical development of new drugs for adults and children with cancer, 2010-2020. J. Natl Cancer Inst. 115, 917\u2013925 (2023).","journal-title":"J. Natl Cancer Inst."},{"key":"64552_CR27","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1093\/jnci\/djaa044","volume":"112","author":"SX Zhang","year":"2020","unstructured":"Zhang, S. X., Fergusson, D. & Kimmelman, J. Proportion of patients in phase I oncology trials receiving treatments that are ultimately approved. J. Natl Cancer Inst. 112, 886\u2013892 (2020).","journal-title":"J. Natl Cancer Inst."},{"key":"64552_CR28","doi-asserted-by":"publisher","first-page":"103726","DOI":"10.1016\/j.drudis.2023.103726","volume":"28","author":"A Schuhmacher","year":"2023","unstructured":"Schuhmacher, A., Hinder, M., von Stegmann Und Stein, A., Hartl, D. & Gassmann, O. Analysis of pharma R&D productivity - a new perspective needed. Drug Discov. Today 28, 103726 (2023).","journal-title":"Drug Discov. Today"},{"key":"64552_CR29","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1016\/j.apsb.2022.02.002","volume":"12","author":"D Sun","year":"2022","unstructured":"Sun, D., Gao, W., Hu, H. & Zhou, S. Why 90% of clinical drug development fails and how to improve it?. Acta Pharm. Sin. B 12, 3049\u20133062 (2022).","journal-title":"Acta Pharm. Sin. B"},{"key":"64552_CR30","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.jacbts.2019.02.005","volume":"4","author":"GA Van Norman","year":"2019","unstructured":"Van Norman, G. A. Phase II trials in drug development and adaptive trial design. JACC Basic Transl. Sci. 4, 428\u2013437 (2019).","journal-title":"JACC Basic Transl. Sci."},{"key":"64552_CR31","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1001\/jama.2019.20288","volume":"323","author":"JJ Darrow","year":"2020","unstructured":"Darrow, J. J., Avorn, J. & Kesselheim, A. S. FDA approval and regulation of pharmaceuticals, 1983-2018. JAMA 323, 164\u2013176 (2020).","journal-title":"JAMA"},{"key":"64552_CR32","volume":"6","author":"DC Zhai","year":"2024","unstructured":"Zhai, D. C., Zhang, Q. Y., Lu, X. L., You, Q. D. & Wang, L. Global first-in-class drugs approved in 2023-2024: breakthroughs and insights. Innovation 6, 100801 (2024).","journal-title":"Innovation"},{"key":"64552_CR33","doi-asserted-by":"crossref","unstructured":"Mullard, A. R&D budgets boom, but success rates falter. Nat. Rev. Drug Discov. 21, 249 (2022).","DOI":"10.1038\/d41573-022-00051-z"},{"key":"64552_CR34","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1056\/NEJMe048225","volume":"351","author":"C De Angelis","year":"2004","unstructured":"De Angelis, C. et al. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. N. Engl. J. Med. 351, 1250\u20131251 (2004).","journal-title":"N. Engl. J. Med."},{"key":"64552_CR35","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1056\/NEJMp1803910","volume":"379","author":"J Avorn","year":"2018","unstructured":"Avorn, J., Kesselheim, A. & Sarpatwari, A. The FDA amendments act of 2007 - assessing its effects a decade later. N. Engl. J. Med. 379, 1097\u20131099 (2018).","journal-title":"N. Engl. J. Med."},{"key":"64552_CR36","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.tips.2023.06.010","volume":"44","author":"FW Pun","year":"2023","unstructured":"Pun, F. W., Ozerov, I. V. & Zhavoronkov, A. AI-powered therapeutic target discovery. Trends Pharm. Sci. 44, 561\u2013572 (2023).","journal-title":"Trends Pharm. Sci."},{"key":"64552_CR37","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.jaci.2017.04.029","volume":"140","author":"DD Patel","year":"2017","unstructured":"Patel, D. D., Antoni, C., Freedman, S. J., Levesque, M. C. & Sundy, J. S. Phase 2 to phase 3 clinical trial transitions: reasons for success and failure in immunologic diseases. J. Allergy Clin. Immunol. 140, 685\u2013687 (2017).","journal-title":"J. Allergy Clin. Immunol."},{"key":"64552_CR38","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nrclinonc.2015.194","volume":"13","author":"KM Wong","year":"2016","unstructured":"Wong, K. M., Capasso, A. & Eckhardt, S. G. The changing landscape of phase I trials in oncology. Nat. Rev. Clin. Oncol. 13, 106\u2013117 (2016).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"64552_CR39","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/nrd4320-c1","volume":"14","author":"DW Lendrem","year":"2015","unstructured":"Lendrem, D. W. et al. Progression-seeking bias and rational optimism in research and development. Nat. Rev. Drug Discov. 14, 219\u2013221 (2015).","journal-title":"Nat. Rev. Drug Discov."},{"key":"64552_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.777698","volume":"8","author":"C Chen","year":"2021","unstructured":"Chen, C. et al. Trends of phase I clinical trials of new drugs in mainland China over the past 10 years (2011-2020). Front. Med. 8, 777698 (2021).","journal-title":"Front. Med."},{"key":"64552_CR41","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/nrd.2017.65","volume":"16","author":"KA Getz","year":"2017","unstructured":"Getz, K. A. & Campo, R. A. Trial watch: trends in clinical trial design complexity. Nat. Rev. Drug Discov. 16, 307 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"64552_CR42","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/S2214-109X(20)30542-8","volume":"9","author":"JJH Park","year":"2021","unstructured":"Park, J. J. H. et al. How COVID-19 has fundamentally changed clinical research in global health. Lancet Glob. Health 9, 711\u2013720 (2021).","journal-title":"Lancet Glob. Health"},{"key":"64552_CR43","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1038\/d41573-020-00059-3","volume":"19","author":"MS Ringel","year":"2020","unstructured":"Ringel, M. S., Scannell, J. W., Baedeker, M. & Schulze, U. Breaking Eroom\u2019s law. Nat. Rev. Drug Discov. 19, 833\u2013834 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"64552_CR44","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1016\/j.drudis.2020.09.004","volume":"25","author":"MS Kinch","year":"2020","unstructured":"Kinch, M. S., Horn, C., Kraft, Z. & Schwartz, T. Expanding roles for academic entrepreneurship in drug discovery. Drug Discov. Today 25, 1905\u20131909 (2020).","journal-title":"Drug Discov. Today"},{"key":"64552_CR45","doi-asserted-by":"publisher","first-page":"3456","DOI":"10.1200\/JCO.22.00033","volume":"40","author":"B De Wilde","year":"2022","unstructured":"De Wilde, B. et al. The critical role of academic clinical trials in pediatric cancer drug approvals: design, conduct, and fit for purpose data for positive regulatory decisions. J. Clin. Oncol. 40, 3456 (2022).","journal-title":"J. Clin. Oncol."},{"key":"64552_CR46","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/d41573-022-00213-z","volume":"22","author":"A Schuhmacher","year":"2023","unstructured":"Schuhmacher, A., Hinder, M., Boger, N., Hartl, D. & Gassmann, O. The significance of blockbusters in the pharmaceutical industry. Nat. Rev. Drug Discov. 22, 177\u2013178 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"64552_CR47","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1111\/cts.12577","volume":"11","author":"T Takebe","year":"2018","unstructured":"Takebe, T., Imai, R. & Ono, S. The current status of drug discovery and development as originated in united states academia: the influence of industrial and academic collaboration on drug discovery and development. Clin. Transl. Sci. 11, 597\u2013606 (2018).","journal-title":"Clin. Transl. Sci."},{"key":"64552_CR48","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/nrd.2017.194","volume":"17","author":"HP Shih","year":"2018","unstructured":"Shih, H. P., Zhang, X. & Aronov, A. M. Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications. Nat. Rev. Drug Discov. 17, 19\u201333 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"64552_CR49","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.tips.2017.06.005","volume":"38","author":"Z Liu","year":"2017","unstructured":"Liu, Z., Delavan, B., Roberts, R. & Tong, W. Lessons learned from two decades of anticancer drugs. Trends Pharm. Sci. 38, 852\u2013872 (2017).","journal-title":"Trends Pharm. Sci."},{"key":"64552_CR50","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/s41571-018-0102-3","volume":"15","author":"SJ Nass","year":"2018","unstructured":"Nass, S. J. et al. Accelerating anticancer drug development - opportunities and trade-offs. Nat. Rev. Clin. Oncol. 15, 777\u2013786 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"64552_CR51","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.ccell.2022.01.007","volume":"40","author":"S Zhao","year":"2022","unstructured":"Zhao, S. et al. Time to raise the bar: transition rate of phase 1 programs on anticancer drugs. Cancer Cell 40, 233\u2013235 (2022).","journal-title":"Cancer Cell"},{"key":"64552_CR52","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.annonc.2022.09.158","volume":"34","author":"D Araujo","year":"2023","unstructured":"Araujo, D. et al. Oncology phase I trial design and conduct: time for a change - MDICT guidelines 2022. Ann. Oncol. 34, 48\u201360 (2023).","journal-title":"Ann. Oncol."},{"key":"64552_CR53","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.drudis.2020.11.009","volume":"26","author":"DC Fernandes","year":"2021","unstructured":"Fernandes, D. C., Reis, R. L. & Oliveira, J. M. Advances in 3D neural, vascular and neurovascular models for drug testing and regenerative medicine. Drug Discov. Today 26, 754\u2013768 (2021).","journal-title":"Drug Discov. Today"},{"key":"64552_CR54","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202003937","volume":"8","author":"W Zhang","year":"2021","unstructured":"Zhang, W., Mehta, A., Tong, Z., Esser, L. & Voelcker, N. H. Development of polymeric nanoparticles for blood-brain barrier transfer-strategies and challenges. Adv. Sci. 8, 2003937 (2021).","journal-title":"Adv. Sci."},{"key":"64552_CR55","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/s41593-018-0236-8","volume":"21","author":"TM Dawson","year":"2018","unstructured":"Dawson, T. M., Golde, T. E. & Lagier-Tourenne, C. Animal models of neurodegenerative diseases. Nat. Neurosci. 21, 1370\u20131379 (2018).","journal-title":"Nat. Neurosci."},{"key":"64552_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2022.06.005","volume":"27","author":"D Kumar","year":"2022","unstructured":"Kumar, D., Md Ashraf, G., Bilgrami, A. L. & Imtaiyaz Hassan, M. Emerging therapeutic developments in neurodegenerative diseases: a clinical investigation. Drug Discov. Today 27, 103305 (2022).","journal-title":"Drug Discov. Today"},{"key":"64552_CR57","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-021-00278-x","volume":"7","author":"E Berntorp","year":"2021","unstructured":"Berntorp, E. et al. Haemophilia. Nat. Rev. Dis. Prim. 7, 45 (2021).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"64552_CR58","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1111\/jth.13717","volume":"15","author":"E Sparkenbaugh","year":"2017","unstructured":"Sparkenbaugh, E. & Pawlinski, R. Prothrombotic aspects of sickle cell disease. J. Thromb. Haemost. 15, 1307\u20131316 (2017).","journal-title":"J. Thromb. Haemost."},{"key":"64552_CR59","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/S0140-6736(20)32722-7","volume":"397","author":"ME Mancuso","year":"2021","unstructured":"Mancuso, M. E., Mahlangu, J. N. & Pipe, S. W. The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing. Lancet 397, 630\u2013640 (2021).","journal-title":"Lancet"},{"key":"64552_CR60","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"S Pushpakom","year":"2019","unstructured":"Pushpakom, S. et al. Drug repurposing: progress, challenges and recommendations. Nat. Rev. Drug Discov. 18, 41\u201358 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"64552_CR61","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/S1470-2045(20)30424-1","volume":"21","author":"AA Tran","year":"2020","unstructured":"Tran, A. A. & Prasad, V. Drug repurposing for cancer treatments: a well-intentioned, but misguided strategy. Lancet Oncol. 21, 1134\u20131136 (2020).","journal-title":"Lancet Oncol."},{"key":"64552_CR62","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/bph.14081","volume":"175","author":"A Papapetropoulos","year":"2018","unstructured":"Papapetropoulos, A. & Szabo, C. Inventing new therapies without reinventing the wheel: the power of drug repurposing. Br. J. Pharm. 175, 165\u2013167 (2018).","journal-title":"Br. J. Pharm."},{"key":"64552_CR63","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.msard.2015.11.007","volume":"5","author":"CD De Gasperis-Brigante","year":"2016","unstructured":"De Gasperis-Brigante, C. D., Parker, J. L., O\u2019Connor, P. W. & Bruno, T. R. Reducing clinical trial risk in multiple sclerosis. Mult. Scler. Relat. Disord. 5, 81\u201388 (2016).","journal-title":"Mult. Scler. Relat. Disord."},{"key":"64552_CR64","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd5524","volume":"13","author":"CG Begley","year":"2021","unstructured":"Begley, C. G. et al. Drug repurposing: misconceptions, challenges, and opportunities for academic researchers. Sci. Transl. Med. 13, eabd5524 (2021).","journal-title":"Sci. Transl. Med."},{"key":"64552_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56690-4","volume":"16","author":"JL Cummings","year":"2025","unstructured":"Cummings, J. L. et al. Drug repurposing for Alzheimer\u2019s disease and other neurodegenerative disorders. Nat. Commun. 16, 1755 (2025).","journal-title":"Nat. Commun."},{"key":"64552_CR66","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1146\/annurev-pharmtox-010818-021625","volume":"59","author":"MC Parrish","year":"2019","unstructured":"Parrish, M. C., Tan, Y. J., Grimes, K. V. & Mochly-Rosen, D. Surviving in the valley of death: opportunities and challenges in translating academic drug discoveries. Annu. Rev. Pharm. Toxicol. 59, 405\u2013421 (2019).","journal-title":"Annu. Rev. Pharm. Toxicol."},{"key":"64552_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2024.103918","volume":"29","author":"AJ Murray","year":"2024","unstructured":"Murray, A. J., Cox, L. R., Adcock, H. V. & Roberts, R. A. Academic drug discovery: challenges and opportunities. Drug Discov. Today 29, 103918 (2024).","journal-title":"Drug Discov. Today"},{"key":"64552_CR68","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1016\/j.drudis.2022.02.015","volume":"27","author":"H Beck","year":"2022","unstructured":"Beck, H., Harter, M., Hass, B., Schmeck, C. & Baerfacker, L. Small molecules and their impact in drug discovery: a perspective on the occasion of the 125th anniversary of the Bayer chemical research laboratory. Drug Discov. Today 27, 1560\u20131574 (2022).","journal-title":"Drug Discov. Today"},{"key":"64552_CR69","doi-asserted-by":"crossref","unstructured":"Lu, R. M. et al. Development of therapeutic antibodies for the treatment of diseases. J. Biomed. Sci. 27, 1 (2020).","DOI":"10.1186\/s12929-019-0592-z"},{"key":"64552_CR70","first-page":"1353","volume":"37","author":"P Janiaud","year":"2021","unstructured":"Janiaud, P., Hemkens, L. G. & Ioannidis, J. P. A. Challenges and lessons learned from COVID-19 trials: should we be doing clinical trials differently?. Can. J. Cardiol. 37, 1353\u20131364 (2021).","journal-title":"Can. J. Cardiol."},{"key":"64552_CR71","doi-asserted-by":"publisher","first-page":"e0013037","DOI":"10.1371\/journal.pntd.0013037","volume":"19","author":"LP Wong","year":"2025","unstructured":"Wong, L. P. et al. Investigating post-COVID-19 confidence in emergency use authorization vaccines: a hypothetical case of mpox. PLoS Negl. Trop. Dis. 19, e0013037 (2025).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"64552_CR72","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/d41573-021-00016-8","volume":"20","author":"M Baedeker","year":"2021","unstructured":"Baedeker, M., Ringel, M. & Schulze, U. 2020 FDA approvals: momentum kept despite COVID-19, but value falls. Nat. Rev. Drug Discov. 20, 92 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"64552_CR73","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1038\/s41551-020-00658-w","volume":"4","author":"N Pardi","year":"2020","unstructured":"Pardi, N. & Weissman, D. Development of vaccines and antivirals for combating viral pandemics. Nat. Biomed. Eng. 4, 1128\u20131133 (2020).","journal-title":"Nat. Biomed. Eng."},{"key":"64552_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2024.108015","volume":"301","author":"L Jin","year":"2025","unstructured":"Jin, L., Zhou, Y., Zhang, S. & Chen, S. J. mRNA vaccine sequence and structure design and optimization: advances and challenges. J. Biol. Chem. 301, 108015 (2025).","journal-title":"J. Biol. Chem."},{"key":"64552_CR75","doi-asserted-by":"publisher","first-page":"221","DOI":"10.7326\/M20-6169","volume":"174","author":"DV Mehrotra","year":"2021","unstructured":"Mehrotra, D. V. et al. Clinical endpoints for evaluating efficacy in COVID-19 vaccine trials. Ann. Intern. Med. 174, 221\u2013228 (2021).","journal-title":"Ann. Intern. Med."},{"key":"64552_CR76","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1016\/j.chom.2021.05.004","volume":"29","author":"SA Lowery","year":"2021","unstructured":"Lowery, S. A., Sariol, A. & Perlman, S. Innate immune and inflammatory responses to SARS-CoV-2: implications for COVID-19. Cell Host Microbe 29, 1052\u20131062 (2021).","journal-title":"Cell Host Microbe"},{"key":"64552_CR77","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/s41392-021-00527-1","volume":"6","author":"C Wang","year":"2021","unstructured":"Wang, C. et al. COVID-19 in early 2021: current status and looking forward. Signal Transduct. Target Ther. 6, 114 (2021).","journal-title":"Signal Transduct. Target Ther."},{"key":"64552_CR78","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.cmi.2023.12.028","volume":"30","author":"DA Sweeney","year":"2024","unstructured":"Sweeney, D. A., Lobo, S. M., Povoa, P. & Kalil, A. C. Choosing immunomodulating therapies for the treatment of COVID-19: recommendations based on placebo-controlled trial evidence. Clin. Microbiol Infect. 30, 611\u2013618 (2024).","journal-title":"Clin. Microbiol Infect."},{"key":"64552_CR79","first-page":"1171","volume":"328","author":"A Slomski","year":"2022","unstructured":"Slomski, A. Repurposed drugs failed to prevent severe COVID-19. JAMA 328, 1171 (2022).","journal-title":"JAMA"},{"key":"64552_CR80","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1136\/jnnp-2019-320879","volume":"90","author":"AE Clout","year":"2019","unstructured":"Clout, A. E., Della Pasqua, O., Hanna, M. G., Orlu, M. & Pitceathly, R. D. S. Drug repurposing in neurological diseases: an integrated approach to reduce trial and error. J. Neurol. Neurosurg. Psychiatry 90, 1270\u20131275 (2019).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"64552_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2025.104390","volume":"30","author":"A Recino","year":"2025","unstructured":"Recino, A., Rayner, M. L. D., Rohn, J. L. & Pasqua, O. D. Therapeutic innovation in drug repurposing: challenges and opportunities. Drug Discov. Today 30, 104390 (2025).","journal-title":"Drug Discov. Today"},{"key":"64552_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.174569","volume":"912","author":"N Mittal","year":"2021","unstructured":"Mittal, N. & Mittal, R. Repurposing old molecules for new indications: defining pillars of success from lessons in the past. Eur. J. Pharm. 912, 174569 (2021).","journal-title":"Eur. J. Pharm."},{"key":"64552_CR83","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1056\/NEJMsr1601330","volume":"376","author":"DA Zarin","year":"2017","unstructured":"Zarin, D. A., Tse, T., Williams, R. J. & Rajakannan, T. Update on trial registration 11 years after the ICMJE policy was established. N. Engl. J. Med. 376, 383\u2013391 (2017).","journal-title":"N. Engl. J. Med."},{"key":"64552_CR84","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1001\/jamainternmed.2021.2036","volume":"181","author":"NJ DeVito","year":"2021","unstructured":"DeVito, N. J. & Goldacre, B. Evaluation of compliance with legal requirements under the FDA amendments act of 2007 for timely registration of clinical trials, data verification, delayed reporting, and trial document submission. JAMA Intern. Med. 181, 1128\u20131130 (2021).","journal-title":"JAMA Intern. Med."},{"key":"64552_CR85","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1056\/NEJMsr1611785","volume":"375","author":"DA Zarin","year":"2016","unstructured":"Zarin, D. A., Tse, T., Williams, R. J. & Carr, S. Trial reporting in ClinicalTrials.gov - the final rule. N. Engl. J. Med. 375, 1998\u20132004 (2016).","journal-title":"N. Engl. J. Med."},{"key":"64552_CR86","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S0140-6736(19)33220-9","volume":"395","author":"NJ DeVito","year":"2020","unstructured":"DeVito, N. J., Bacon, S. & Goldacre, B. Compliance with legal requirement to report clinical trial results on ClinicalTrials.gov: a cohort study. Lancet 395, 361\u2013369 (2020).","journal-title":"Lancet"},{"key":"64552_CR87","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.cell.2016.04.021","volume":"165","author":"SA Lipton","year":"2016","unstructured":"Lipton, S. A. & Nordstedt, C. Partnering with big pharma-what academics need to know. Cell 165, 512\u2013515 (2016).","journal-title":"Cell"},{"key":"64552_CR88","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1172\/JCI129122","volume":"129","author":"JS Flier","year":"2019","unstructured":"Flier, J. S. Academia and industry: allocating credit for discovery and development of new therapies. J. Clin. Invest. 129, 2172\u20132174 (2019).","journal-title":"J. Clin. Invest."},{"key":"64552_CR89","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1056\/NEJMra1612575","volume":"376","author":"BW Ramsey","year":"2017","unstructured":"Ramsey, B. W., Nepom, G. T. & Lonial, S. Academic, foundation, and industry collaboration in finding new therapies. N. Engl. J. Med. 376, 1762\u20131769 (2017).","journal-title":"N. Engl. J. Med."},{"key":"64552_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2025.104317","volume":"30","author":"E Peeva","year":"2025","unstructured":"Peeva, E. et al. Unlocking disease insights to facilitate drug development: pharmaceutical industry-academia collaborations in inflammation and immunology. Drug Discov. Today 30, 104317 (2025).","journal-title":"Drug Discov. Today"},{"key":"64552_CR91","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3389\/fphar.2016.00461","volume":"7","author":"O Yildirim","year":"2016","unstructured":"Yildirim, O., Gottwald, M., Schuler, P. & Michel, M. C. Opportunities and challenges for drug development: public-private partnerships, adaptive designs and big data. Front. Pharm. 7, 461 (2016).","journal-title":"Front. Pharm."},{"key":"64552_CR92","doi-asserted-by":"publisher","first-page":"k3654","DOI":"10.1136\/bmj.k3654","volume":"363","author":"K Rasmussen","year":"2018","unstructured":"Rasmussen, K., Bero, L., Redberg, R., Gotzsche, P. C. & Lundh, A. Collaboration between academics and industry in clinical trials: cross sectional study of publications and survey of lead academic authors. BMJ 363, k3654 (2018).","journal-title":"BMJ"},{"key":"64552_CR93","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/cpt.2789","volume":"113","author":"MJ Kallio","year":"2023","unstructured":"Kallio, M. J. et al. Translating academic drug discovery into clinical development: a survey of the awareness of regulatory support and requirements among stakeholders in Europe. Clin. Pharm. Ther. 113, 349\u2013359 (2023).","journal-title":"Clin. Pharm. Ther."},{"key":"64552_CR94","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.drudis.2020.10.017","volume":"26","author":"V Starokozhko","year":"2021","unstructured":"Starokozhko, V. et al. Strengthening regulatory science in academia: STARS, an EU initiative to bridge the translational gap. Drug Discov. Today 26, 283\u2013288 (2021).","journal-title":"Drug Discov. Today"},{"key":"64552_CR95","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1080\/17460441.2023.2284824","volume":"19","author":"M Everts","year":"2024","unstructured":"Everts, M. & Drew, M. Successfully navigating the valley of death: the importance of accelerators to support academic drug discovery and development. Expert Opin. Drug Discov. 19, 253\u2013258 (2024).","journal-title":"Expert Opin. Drug Discov."},{"key":"64552_CR96","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/d41573-023-00021-z","volume":"22","author":"V Starokozhko","year":"2023","unstructured":"Starokozhko, V. et al. Strategic recommendations from the STARS project to foster academic drug development. Nat. Rev. Drug Discov. 22, 251\u2013252 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"64552_CR97","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s43018-023-00516-z","volume":"4","author":"S Zinn","year":"2023","unstructured":"Zinn, S. et al. Advances in antibody-based therapy in oncology. Nat. Cancer 4, 165\u2013180 (2023).","journal-title":"Nat. Cancer"},{"key":"64552_CR98","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41392-024-01760-0","volume":"9","author":"XP Duan","year":"2024","unstructured":"Duan, X. P. et al. New clinical trial design in precision medicine: discovery, development and direction. Signal Transduct. Target Ther. 9, 57 (2024).","journal-title":"Signal Transduct. Target Ther."},{"key":"64552_CR99","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.drudis.2015.02.007","volume":"20","author":"C Xia","year":"2015","unstructured":"Xia, C. & Gautam, A. Biopharma CRO industry in China: landscape and opportunities. Drug Discov. Today 20, 794\u2013798 (2015).","journal-title":"Drug Discov. Today"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-64552-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-64552-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-64552-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T12:03:50Z","timestamp":1761739430000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-64552-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":99,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["64552"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-64552-2","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,29]]},"assertion":[{"value":"22 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9537"}}